FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to pharmaceutically acceptable crystalline or amorphous salts of D-isoglutamyl-D-tryptophan, methods of their obtaining, pharmaceutical compositions, containing them, and their application for obtaining pharmaceutical compositions for treatment of different conditions and/or diseases. In particular claimed invention relates to potassium salt of D-isoglutamyl-D-tryptophan (1:1) and magnesium salt of D-isoglutamyl-D-tryptophan (2:1).
EFFECT: obtaining pharmaceutically acceptable crystalline or amorphous salts of D-isoglutamyl-D-tryptophan.
22 cl, 15 dwg, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CRYSTALLINE D-ISOGLUTAMYL-D-TRYPTOPHAN AND MONOAMMONIUM SALT OF D-ISOGUTAMYL-D-TRYPTOPHAN | 2007 |
|
RU2483077C2 |
| CRYSTALLINE FORMS OF MONOSODIUM SALT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | 2008 |
|
RU2476440C2 |
| METHOD OF PRODUCING MONOSODIUM SALT OF ISOGLUTAMYL-TRYPTOPHAN | 2019 |
|
RU2703991C1 |
| TARTRATE 3-((1R,3R)-1-(2,6-DIFLUORINE-4-((1-(3- FLUOROPROPYL)AZETIDINE-3-YL)AMINO)PHENYL)-3-METHYL-1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-b]INDOLE-2-YL)-2,2-DIFLUOROPROPANE-1-OL, ITS SOLID FORMS, METHOD OF ITS PREPARATION AND THEIR APPLICATION | 2019 |
|
RU2809220C2 |
| NEW CRYSTALLINE FORMS | 2007 |
|
RU2446156C2 |
| SALTS AND CRYSTALLINE FORMS | 2014 |
|
RU2654855C2 |
| PHARMACEUTICAL PREPARATION WITH IMMEDIATE RELEASE | 2003 |
|
RU2351314C2 |
| CRYSTALLINE FORMS OF THE TLR7/TLR8 INHIBITOR | 2019 |
|
RU2792005C2 |
| SOLID FORMS OF CEFTOLOZANE | 2014 |
|
RU2703457C2 |
| CRYSTALLINE OR AMORPHOUS FORM OF FXR AGONISTS BEING STEROID DERIVATIVES, THEIR PRODUCTION METHOD AND THEIR USE | 2018 |
|
RU2800751C2 |
